← Leaderboards
Alnawaz Rehemtulla
University Of Michigan At Ann Arbor
$11,324,080
Attributed
$13,725,964
Total exposure
14
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,725,964 · 14
By mechanism
R01$6,397,902 · 4
P01$4,225,108 · 3
P50$2,240,270 · 3
U54$309,336 · 1
R21$276,975 · 1
R29$203,000 · 1
Top collaborators
- Judith S Leopold5 shared
- Nouri Neamati5 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Elizabeth R Lawlor$9,932,316
- Brian D. Ross$27,286,369
- Maria G Castro$22,126,725
- Ashley Melnick$91,535
- Lam Cheung Tsoi$2,502,429
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsBaseMalignant NeoplasmsTumorSignal TransductionIn VivoLeadMolecular ImagingIn VitroImageMonitorResponsePathway InteractionsPhosphotransferasesDesignMouse ModelNeoplastic CellReporterCancer TherapyPharmaceutical PreparationsDoseTechnologyMediatingInhibitor/Antagonist
Grant awards (48)
Core C: Radiosensitization Core$118,944
P50 · FY2025 · CA · contact PI
TTD$73,373
P41 · FY2025 · EB · contact PI
Core C: Radiosensitization Core$114,186
P50 · FY2024 · CA · contact PI
Combating Resistance of Pancreatic Cancer with a First-in-Class Dual Targeted PI3K/EGFR Inhibitor$474,721
R01 · FY2023 · CA
Core C: Radiosensitization Core$121,231
P50 · FY2023 · CA · contact PI
Combating Resistance of Pancreatic Cancer with a First-in-Class Dual Targeted PI3K/EGFR Inhibitor$474,721
R01 · FY2022 · CA
Combating Resistance of Pancreatic Cancer with a First-in-Class Dual Targeted PI3K/EGFR Inhibitor$484,410
R01 · FY2021 · CA
Combating Resistance of Pancreatic Cancer with a First-in-Class Dual Targeted PI3K/EGFR Inhibitor$484,410
R01 · FY2020 · CA
Combating Resistance of Pancreatic Cancer with a First-in-Class Dual Targeted PI3K/EGFR Inhibitor$484,410
R01 · FY2019 · CA
Efficacy of PDI inhibitors in glioblastoma$459,059
R01 · FY2019 · CA
Efficacy of PDI inhibitors in glioblastoma$483,547
R01 · FY2018 · CA
Efficacy of PDI inhibitors in glioblastoma$486,120
R01 · FY2017 · CA
Identification of Genetic Alterations Responsible for Primary GBM Clonal Evoluti$458,156
P01 · FY2017 · CA · contact PI
Efficacy of PDI inhibitors in glioblastoma$486,120
R01 · FY2016 · CA
Identification of Genetic Alterations Responsible for Primary GBM Clonal Evoluti$439,511
P01 · FY2016 · CA · contact PI
Efficacy of PDI inhibitors in glioblastoma$486,251
R01 · FY2015 · CA
Identification of Genetic Alterations Responsible for Primary GBM Clonal Evoluti$439,642
P01 · FY2015 · CA · contact PI
Identification of Genetic Alterations Responsible for Primary GBM Clonal Evoluti$426,766
P01 · FY2014 · CA · contact PI
Identification of Genetic Alterations Responsible for Primary GBM Clonal Evoluti$451,755
P01 · FY2013 · CA · contact PI
Proj 2: Molecular Imaging of Cell Surface Receptors in Cancer$326,391
P50 · FY2012 · CA · contact PI
Task Specific Project 3$53,331
U54 · FY2012 · CA · contact PI
Devel. of Mol. Imaging Tools for Non-Invasive Monitoring of Drug Target Interact.$403,455
P01 · FY2011 · CA · contact PI
Proj 2: Molecular Imaging of Cell Surface Receptors in Cancer$374,695
P50 · FY2011 · CA · contact PI
Molecular Imaging of Phospho-FADD and its role in resistance to therapy$279,926
R01 · FY2011 · CA · contact PI
Task Specific Project 3$59,429
U54 · FY2011 · CA · contact PI
Proj 2: Molecular Imaging of Cell Surface Receptors in Cancer$471,068
P50 · FY2010 · CA · contact PI
Devel. of Mol. Imaging Tools for Non-Invasive Monitoring of Drug Target Interact.$399,208
P01 · FY2010 · CA · contact PI
Molecular Imaging of Phospho-FADD and its role in resistance to therapy$288,584
R01 · FY2010 · CA · contact PI
Task Specific Project 3$74,113
U54 · FY2010 · CA · contact PI
Proj 2: Molecular Imaging of Cell Surface Receptors in Cancer$437,219
P50 · FY2009 · CA · contact PI
Devel. of Mol. Imaging Tools for Non-Invasive Monitoring of Drug Target Interact.$422,561
P01 · FY2009 · CA · contact PI
Molecular Imaging of Phospho-FADD and its role in resistance to therapy$288,584
R01 · FY2009 · CA · contact PI
HTS for FADD kinase inhibitors using molecular imaging$208,575
R21 · FY2009 · CA · contact PI
Task Specific Project 3$74,729
U54 · FY2009 · CA · contact PI
Devel. of Mol. Imaging Tools for Non-Invasive Monitoring of Drug Target Interact.$411,121
P01 · FY2008 · CA · contact PI
Molecular Imaging of Phospho-FADD and its role in resistance to therapy$288,584
R01 · FY2008 · CA · contact PI
Proj 2: Molecular Imaging of Cell Surface Receptors in Cancer$276,536
P50 · FY2008 · CA · contact PI
HTS for FADD kinase inhibitors using molecular imaging$68,400
R21 · FY2008 · CA · contact PI
Task Specific Project 3$47,734
U54 · FY2008 · CA · contact PI
Devel. of Mol. Imaging Tools for Non-Invasive Monitoring of Drug Target Interact.$372,933
P01 · FY2007 · CA · contact PI
Molecular Imaging of Phospho-FADD and its role in resistance to therapy$288,800
R01 · FY2007 · CA · contact PI
Imaging of Carcinogenesis$0
P50 · FY2002 · CA
Imaging of Carcinogenesis$0
P50 · FY2002 · CA
MR FOR DETECTION AND IMAGING OF GENE DELIVERY/FUNCTION$0
P01 · FY2002 · CA
NOVEL ENZYME/PRODRUG STRATEGY FOR CANCER GENE THERAPY$101,500
R29 · FY2001 · CA
MR FOR DETECTION AND IMAGING OF GENE DELIVERY/FUNCTION$0
P01 · FY2001 · CA
MOLECULAR MEDIATORS OF RADIATION-INDUCED APOPTOSIS$159,655
R01 · FY2000 · CA
NOVEL ENZYME/PRODRUG STRATEGY FOR CANCER GENE THERAPY$101,500
R29 · FY2000 · CA